• Does Colony Stimulating Factor Increase Survival of Patients with Alcoholic Hepatitis?

Does Colony Stimulating Factor Increase Survival of Patients with Alcoholic Hepatitis?

In a pilot study from the October issue of Clinical Gastroenterology and Hepatology, colony stimulating factor 3 (CSF3, also called GCSF) improved liver function and increased survival times in patients with severe alcohol-associated hepatitis (AH), compared with standard therapy. Addition of N-acetyl cysteine (NAC) to GCSF did not improve patient outcomes. Patients

Read more
  • A Window of Opportunity for Treating Patients with Cirrhosis

A Window of Opportunity for Treating Patients with Cirrhosis

Despite the ability of nonselective β blockers (NSBBs) to reduce portal pressure and lower the risk of variceal hemorrhage in patients with cirrhosis, these drugs have detrimental effects on those who have developed spontaneous bacterial peritonitis, researchers show in the June issue of Gastroenterology. Variceal hemorrhage, the most common lethal complication of

Read more

Can We Prevent Portal Vein Thrombosis in Patients With Cirrhosis?

The anti-clotting agent enoxaparin prevents portal vein thrombosis (PVT) in patients with cirrhosis, according to the November issue of Gastroenterology. PVT can lead to portal hypertension and reduce the blood supply to the liver—some patients with acute or extensive PVT develop severe gastrointestinal bleeding, ascites, or intestinal ischemia, which can progress and become

Read more